RenovoRx, Inc. (NASDAQ:RNXT – Free Report) – Investment analysts at Ascendiant Capital Markets raised their FY2026 earnings per share estimates for shares of RenovoRx in a research note issued to investors on Thursday, August 27th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will post earnings of ($0.27) per share for the year, up from their previous forecast of ($0.29). Ascendiant Capital Markets currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for RenovoRx’s current full-year earnings is ($0.25) per share. Ascendiant Capital Markets also issued estimates for RenovoRx’s Q4 2026 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.02) EPS and FY2027 earnings at ($0.20) EPS.
RenovoRx (NASDAQ:RNXT – Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. RenovoRx had a negative net margin of 621.71% and a negative return on equity of 135.11%. The company had revenue of $0.91 million during the quarter, compared to analysts’ expectations of $0.70 million.
View Our Latest Stock Analysis on RNXT
RenovoRx Stock Performance
RNXT stock opened at $2.11 on Wednesday. The stock’s 50 day moving average price is $1.10 and its 200 day moving average price is $0.98. The firm has a market cap of $95.22 million, a P/E ratio of -6.81 and a beta of 1.12. RenovoRx has a 1 year low of $0.70 and a 1 year high of $2.20.
Hedge Funds Weigh In On RenovoRx
Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its stake in RenovoRx by 9.9% in the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock worth $467,000 after buying an additional 31,730 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in shares of RenovoRx during the 2nd quarter valued at about $98,000. Citadel Advisors LLC purchased a new position in shares of RenovoRx during the 3rd quarter worth about $154,000. Wealthspire Advisors LLC acquired a new stake in shares of RenovoRx in the fourth quarter worth approximately $212,000. Finally, Bleichroeder LP boosted its position in shares of RenovoRx by 11.4% in the fourth quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock worth $504,000 after acquiring an additional 61,379 shares during the last quarter. 3.10% of the stock is currently owned by hedge funds and other institutional investors.
RenovoRx Company Profile
RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.
RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.
Featured Stories
- Five stocks we like better than RenovoRx
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.
